DUBLIN , July 11, 2022 /PRNewswire/ -- The "Human Growth Hormone Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global human growth hormone market reached a value of US$ 4.8 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 7.9 Billion by 2027, exhibiting a CAGR of 8.66% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor. HGH is a peptide hormone that is produced by the pituitary gland to stimulate growth in children and adults. The hormone primarily regulates growth, regeneration, repair, reproduction and metabolism of the cells, thus contributing to the overall development of the body. It also regulates body fluids, fat metabolism and bone and muscle growth. The deficiency of HGH can increase the risk of diseases and fat accumulation, whereas higher levels can cause gigantism in children and acromegaly, muscle-wasting disease and short bowel syndrome in adults. The increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes.
Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. Furthermore, increasing health consciousness among the masses and growing awareness regarding the preventive measures against endocrine disorders, are providing a boost to the market growth.
Various disorders, such as Prader-Willi syndrome (PWS) and idiopathic short stature (ISS), are caused by the deficiency of growth hormones in the body that can be treated using medically synthesized HGH. Other factors, including a rising utilization of HGH as performance enhancers by bodybuilders, along with the development of recombinant human growth hormone (rHGH), are projected to drive the market further.
The competitive landscape of the industry has also been examined with some of the key players being Eli Lilly and Company, EMD Serono Inc., F. Hoffmann-La Roche AG, Ferring B.V., Genentech Inc., Ipsen, Merck KGaA, Novartis AG, Novo Nordisk, Pfizer Inc., Sandoz, etc. Key Questions Answered in This Report:
How has the global human growth hormone market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global human growth hormone market?
What are the key regional markets?
What is the breakup of the market based on the application?
What is the breakup of the market based on the distribution channel?
What is the breakup of the market based on the route of administration?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global human growth hormone market and who are the key players?
What is the degree of competition in the industry?
Key Topics Covered: 1 Preface 2 Scope and Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Human Growth Hormone Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Application 6.1 Growth Hormone (GH) Deficiency 6.1.1 Market Trends 6.1.2 Major Types 6.1.2.1 Adult GH Deficiency 6.1.2.2 Pediatric GH Deficiency 6.1.3 Market Forecast 6.2 Turner Syndrome 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Idiopathic Short Stature (ISS) 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Prader-Willi Syndrome (PWS) 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Small for Gestational Age 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Others 6.6.1 Market Trends 6.6.2 Market Forecast 7 Market Breakup by Distribution Channel 7.1 Hospital Pharmacy 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Retail Pharmacy 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Online Pharmacy 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Others 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Route of Administration 8.1 Intravenous 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Intramuscular 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Subcutaneous 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Oral 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Region
10 SWOT Analysis 11 Value Chain Analysis 12 Porters Five Forces Analysis
13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 Eli Lilly and Company 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 EMD Serono Inc. 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.3 F. Hoffmann-La Roche AG 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.3.3 SWOT Analysis 13.3.4 Ferring B.V. 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.5 Genentech Inc. 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 SWOT Analysis 13.3.6 Ipsen 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.6.3 Financials 13.3.7 Merck KGaA 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.8 Novartis AG 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.9 Novo Nordisk 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.10 Pfizer Inc. 13.3.10.1 Company Overview 13.3.10.2 Product Portfolio 13.3.10.3 Financials 13.3.10.4 SWOT Analysis 13.3.11 Sandoz 13.3.11.1 Company Overview 13.3.11.2 Product Portfolio
For more information about this report visit https://www.researchandmarkets.com/r/tv71e
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/7-9-billion-worldwide-human-growth-hormone-industry-to-2027---featuring-genentech-ipsen-merck-and-novartis-among-others-301583734.html
Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) is joining its tech peers in a stock split. The trillion-dollar tech giant, which is the parent company of Google, plans to do a 20:1 stock split on Friday, July 15. If you're aiming to buy Alphabet before the stock split, the clock is ticking.
Rogers knows how to survive — and thrive — in turbulent times.
For nearly six decades, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett has stood head and shoulders above most money managers. Since taking the reins of Berkshire in 1965, Buffett has overseen the creation of more than $610 billion in value for shareholders, as well as led the company's Class A shares (BRK.A) to an aggregate return in excess of 3,600,000%. Given the Oracle of Omaha's incredible track record, investors tend to pay close attention to what he and his investing team are buying and selling.
Mining stocks could capitulate given waning demand for industrial metals
Inflation is running hot at 9%. Suze likes this asset to beat it.
Citigroup's latest earnings beat means that it could be priced fairly for once
The market is unstable. Your portfolio doesn’t need to be.
Russia is positioning itself to engage in 'expropriation blackmail,' according to Mark Dixon, founder of the Moral Rating Agency.
Yahoo Finance Live examines several of today's trending stocks, including China's tech crackdowns on Alibaba for private data hacks and the outlook for cannabis stocks as American and German lawmakers on legalization bills.
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
U.S. stocks advanced early Friday as Wall Street attempted to shake off this week’s losses. Sentiment was buoyed by better-than-expected retail sales data and a strong earnings report from Citigroup.
MARK HULBERT A gutsy contrarian bet right now is that the strong U.S. dollar will weaken, particularly versus the euro. A secondary bold bet is that U.S. stocks will lag international equities. Dollar weakness would represent a reversal of a trend dating back several years.
The Oracle of Omaha knows how to beat inflation. So ride his coattails.
Yahoo Finance's Rachelle Akuffo discusses why Pinterest stock is popping on Thursday.
Every investor wants to see his stocks pay off – or he wouldn’t be in the markets. But finding the right investment, the ‘one’ that will bring profits, can sometimes be challenging, especially in today's market conditions. The two simplest courses of action an investor can take to ensure solid returns are based on common sense. The first is to buy low and sell high. That is, find a cheap stock with sound fundamentals and good prospects for growth – and buy in to take advantage of the growth pote
Alphabet stock will undergo a 20-for-1 stock split on July 18. Here's how to trade the stock into the event.
Alphabet's stock split will take place after market close on July 15, and you'll notice extra shares in your account if you bought Alphabet before the deadline.
Intel ( ) is the bearer of additional bad news. The chip giant will give an extra blow to consumers and businesses concerned about the health of the economy. For several weeks in fact, consumers have seen their bills for groceries and other products increase.
While Google could get a boost from a 20-for-1 stock split set for Friday, both AMZN stock and SHOP stock have retreated since their recent stock splits.
High-yielding dividend stocks may look like an attractive buy at first glance, but high returns are usually high for a reason -- there's a risk. Every stock has its own unique risk factors. Market volatility, short or long-term headwinds inhibiting the company's ability to grow, or poor management decisions like taking on too much debt are just a few reasons a stock's dividend yields are high and thus, carrying risk.